1st Quarter - Report

VIATRIS INC. for VIATRIS INC

Firm
Client
Income
—
Expenses
$610,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Trans Pacific Partnership(TPP), Intellectual property provisions related to pharmaceuticals

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
NAWEL LILLIAN ROJKJAER —
NIMISH SHAH —

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); White House Office; SENATE; Federal Trade Commission (FTC)

Copyright/Patent/Trademark CPT

Patent reform proposals, use of inter partes review (IPR) challenges of pharmaceutical and biotechnology patents

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
NIMISH SHAH —

Contacted: Federal Trade Commission (FTC); HOUSE OF REPRESENTATIVES; SENATE; White House Office; Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR)

Health Issues HCR

Senate Health, Education, Labor and Pensions Committee's Innovation for Healthier Americans initiative Drug Supply Chain Security Act implementation of pharmaceutical distribution REMs program, H.R. 2841 FAST generics Act, Senate REMS proposed legislation S. 1972 Airline Access to Emergency Epinephrine Act of 2015, Anaphylaxis awareness, access to epinephrine auto injector; S. 2658 Federal Aviation Administration Reauthorization Act of 2016 S. 2615 Increasing Competition in Pharmaceuticals Act, H.R. 4784 Lower Drug Costs through Competition Act, generic medicines pricing issues

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
MARC SCHLOSS New Special Assistant to Senator Edward M. Kennedy
NIMISH SHAH —

Contacted: Federal Trade Commission (FTC); U.S. Trade Representative (USTR); White House Office; Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 2658 (114th), H.R. 2841 (114th), S. 1972 (114th), H.R. 4784 (114th), S. 2615 (114th)

Budget/Appropriations BUD

Issues related to implementation of the Generic Drug User Fee Agreement (GDUFA), FDA funding Medicaid Generic Drug Rebate, HR. 1314 - Bipartisan Budget Act of 2015, S. 1364- Medicaid Generic Drug Price Fairness Act of 2015

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
NIMISH SHAH —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); Federal Trade Commission (FTC); White House Office; Health & Human Services, Dept of (HHS)

Bills named: S. 1364 (114th), H.R. 1314 (114th)

Foreign entities

Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.

EntityCountryPrincipal place of businessOwnershipContribution declared
MYLAN NV United Kingdom United Kingdom 100.0% —
MYLAN HOLDINGS LIMITED United Kingdom United Kingdom 100.0% —

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.